Since the first demonstrations of the differentiation of pluripotent stem cells to produce functional human cellular models such as cardiomyocytes, the scientific community has been captivated [1, 2••, 3]. In the time since that seminal work, the field has been catapulted forward by the demonstration that adult somatic cells can be reprogrammed to an induced state of pluripotency [4••], and more recently by the development of efficient and sophisticated genome editing tools [5••, 6••, 7], which together afford a theoretically unlimited supply of relevant genetic disease models. In particular, many of the early successes with induced pluripotent stem cell technology have been realized with cardiac arrhythmia syndromes [8••, 9-15]. There is interest in applying stem cell models in large-scale screens to discover novel therapeutics or drug toxicities. This manuscript aims to discuss the potential role of hPSC-derived cardiomyocyte models in therapeutic arrhythmia screens and review recent advances in the field that bring us closer to this reality.
Introduction
A major advance in disease modeling has been the demonstration that human induced pluripotent stem cell (hiPSC) technology can faithfully recapitulate many human diseases, including cardiac arrhythmia syndromes [10, 16, 14] . [8••, 9-15] , though increasingly, other cardiac diseases have been modeled, such as familial hypertrophic and dilated cardiomyopathy [17, 18] . Importantly, several of these diseases lack targeted therapeutics that directly address their respective physiological defects. In addition to these unmet needs, stem-cell-derived models may hold promise in evaluation of drug-induced QT prolongation, one of the most common causes of post-market drug withdrawal, which remains difficult to predict in the pre-clinical setting [19] . Enthusiasm has been significant for applying stem-cell models to large-scale screens for both novel therapeutics and cardiotoxicity evaluations [20••, 21, 22] . However, most of the early studies in the stem cell field were limited in scope, despite being conceptually innovative. In recent years, the techniques for human pluripotent stem cell culture and cardiac differentiation have dramatically improved [23••, 24, 25] . This review will focus on the role that stem cell models can play in cardiac arrhythmia-related drug screens, and discuss the necessary steps to realize their potential.
Most of the initial cardiac diso r d e r s t o b e m o d e l e d w i t h h i P S C -d e r i v e d cardiomyocytes (hiPSC-CM) have been Mendelian arrhythmia syndromes

Characteristics and relevance of stem-cell-derived cardiomyocytes
The contribution of any particular model is critically dependent on how faithfully it represents the native in vivo condition-in this case, a mature adult human cardiomyocyte (CM). As adult ventricular CMs are obtained only invasively and thereby in short supply, most studies characterizing the properties of human pluripotent stem cell derived cardiomyocytes (hPSC-CM) to date have compared parameters to previously published values [26] .
Morphologically, most studies have reported that hPSC-CMs, both hiPSCCMs and human embryonic stem cell-derived cardiomyocytes (hESC-CMs), are markedly smaller than adult CMs and lack organized sarcomeres and Ttubules, with a gene expression profile more closely resembling that of fetal CMs [27•] . These features of immaturity are similar to the immature electrical parameters recorded by patch clamp electrophysiology [27•, 28, 29•] . In contrast to adult human CMs, hPSC-CMs bear relatively depolarized diastolic potentials, slower action potential upstroke velocities, and spontaneous electrical activity [30] .
In terms of action potential shape, most investigators have noted the appearance of three distinct hPSC-CM action potential subtypes, classified as ventricular-like, atrial-like, and nodal-like [28] . However, it has been acknowledged that there is a great deal of heterogeneity of AP characteristics reported between cell lines [31] Individual currents have also been extensively studied in hPSC-CMs using voltage clamp electrophysiology, demonstrating the presence of the major currents I Na , I Kr , I Ks , I Ca,L , and I to [2••, 34•, 35, 36] . Unlike mature atrial and ventricular adult CMs, hPSC-CMs also universally feature a prominent funny current, I f , and an absent or minimal inward rectifier, I K1 [37] . Furthermore, a rather large proportion of the Ca 2+ release during an hPSC-CM action potential is IP 3 -sensitive [38] . [28, 36] , and various inhibitors of Na currents [35, 41] . Despite many subtle and some more substantive differences between hPSC-CMs and adult CMs, the action potentials and component currents do bear remarkable similarity, prompting hope that hPSCCMs can recapitulate the adult CM intricacies more accurately than common animal models or heterologous expression systems.
Arrhythmia syndromes modeled in hPSC-CMs
Screens utilizing hPSC-CM models may aim to discover novel therapeutics, but could also be used to detect cardiotoxicity in either healthy or diseased states. In considering the value of therapeutic and toxicological screens using arrhythmic disease models, it is helpful to briefly review progress thus far (Table 1) .
LQTS -The Long-QT Syndrome is characterized by a prolongation in the QT interval, the cellular correlate of which is the AP duration. In 2010, seminal work featured action potential recordings from iPSC-CMs derived from two patients harboring mutations in KCNQ1 (LQT1), encoding the alpha subunit of the channel mediating the I Ks current [8••] . Other iPSC-derived LQT models have since been reported for LQT1 [42] , LQT2 (I Kr deficiency) [9, 10, 43] , LQT3 (persistence of late I Na ) and LQT8/ Timothy syndrome [11] . The quintessential feature of these has been demonstration of prolonged AP duration, as well as arrhythmogenic elements such as EADs. Importantly, the responses to drugs such as isoproterenol-induced EADs in LQT1 [8••] , faithfully recapitulate expected clinical features of the respective disorders. Models of LQT3 syndrome, caused by a gain of function in I Na,late that prolongs inward current over the plateau phase have had mixed results. Ma et al. reported significant APD prolongation in iPSC-CMs derived from a patient with a V1763M mutation in SCN5A, which was reversible by mexilitine treatment [44] , and Davis et al. reported similar results in cells derived from a patient with a clinical overlap syndrome with Brugada [12] . Another study of LQT3 hiPSC-CMs demonstrated variable APD prolongation not reaching statistical significance [45] . Finally, other investigators have chosen not to report AP comparisons from LQT3 hiPSC-CMs, reasoning that the relatively depolarized membrane potential in hPSC-CMs, compared to their adult counterparts, inactivates a large proportion of the Na + channel, which is thereby unable to contribute to the AP shape [46] . Supporting this notion, the I Na,late modulator ATX has been reported to have no apparent effect on AP duration [47] . 
Catecholaminergic polymorphic ventricular tachycardia (CPVT)
Several groups have published hiPSC-CM models derived from patients with CPVT, caused by gain of function mutations in RYR2 [13, [48] [49] [50] or loss of function in CASQ2 [51] , and characterized by susceptibility of the sarcoplasmic reticulum to premature calcium release when stimulated by catecholamines. In the CPVT1 models, as in other studies of Ca 2+ handling in hPSC-CMs [38, 52] , transients were evident upon application of caffeine and abolished by ryanodine, suggesting the presence of functional SR and ryanodine receptors (RyR). However, as hPSC-CM models are deficient in ttubules, and Ca 2+ wavefronts have been noted to be slow, suggesting that coupling between L-type Ca 2+ channels and SR mediated Ca 2+ release may be impaired. Thus, despite increased Ca 2+ transients in CPVT hiPSC-CM models, the physiologic details of calcium handling may be less faithful to the native disease condition [27•] . Furthermore, the CASQ2 mutant hiPSC-CMs reported by Novak et al. feature action potential prolongation that differs substantially from the clinical features of the condition [51] .
Arrhythmogenic right ventrcular cardiomyopathy (ARVC)
Arrhythmogenic right ventricular cardiomyopathy (ARVC) is marked by defects in desmosomal proteins leading to fibrofatty replacement of the right ventricular myocardium with age and increased incidence of ventricular arrhythmias. Three studies have produced hiPSC-CM models from patients with mutations in PKP2, the most frequently responsible gene for ARVC [53, 15, 14] . These reports revealed accumulation of intracellular lipid in response to lipogenic stimuli. Electrophysiological differences were subtle, with slightly higher mean diastolic potential and prolonged APD noted in one study [14] , and prolonged field potential rise time by multi-electrode array in another [53] , possibly reflecting slowed conduction and impaired coupling.
Other cardiac diseases
hPSC-CM models of familial forms of hypertrophic cardiomyopathy [18] , dilated cardiomyopathy [17] , LEOPARD syndrome, Pompe's disease [54] , and other disease have been reported elsewhere. While these clinical syndromes may be accompanied by arrhythmias, we considered them to be outside of the scope of this review.
Standardization is a necessary step
Original methods of cardiac differentiation from hPSCs relied on spontaneous differentiation of aggregates formed from hPSCs known as embryoid bodies, a process with low efficiency and high variability between cell lines [55] . In contrast, current techniques aim to increase efficiency by recapitulating key developmental cues in embryonic cardiogenesis [56] . In general, there are three frequently reported methods: embryoid body differentiation combined with sequential addition of key growth factors [57] , co-culture with visceral endoderm-like cells [ [60] , DMSO [61] , or in the case of the monolayer technique, an extracellular matrix sandwich [23••] , a method yielding highly efficient preparations of cardiomyocytes. However, efficiency varies even with these protocols, which in turn must be additionally optimized for different cell lines. In parallel, efforts have focused on enriching existing populations of differentiated mixtures of cells derived from hPSCs for cardiomyocytes [62] , such as by Percoll gradient [3] , genetic selection by fluorescence or antibiotic resistance [63, 64, 65 •], selection by oxidative metabolic capacity [66] , and sorting by mitochondrial content [67] or cardiomyocyte cell surface markers such as SIRPA [68] or VCAM-1 [69] .
Facilitating the maturation of hPSC-CMs has also been an important area of investigation, as prolongation of time in culture alone is insufficient. Each method of differentiation above involves culturing cells on a fixed protein substrate on a two-dimensional culture platform within an incubator controlling physiological temperature and CO 2 levels. While this embodiment aligns well with the infrastructure of most academic research laboratories, the conditions differ markedly from the in vivo environment, with the loss of three-dimensional ultrastructure and associated cellular contacts and mechanical stresses. One strategy to assist maturation encompasses growth on engineered substrates such as "biowires" to induce structural alignment and mechanical load [70] . Other strategies have involved genetic introduction of deficient rectifying currents accompanied by electrical field pacing [71] , manipulation of bioenergetics [72••, 14] , and other techniques. None of these has been adopted on a widespread level or has been shown to scale up for generation of the large supplies of cardiomyocytes necessary for high-throughput applications. An additional variable to consider is the time point after differentiation for cellular recordings, which may in turn depend on the differentiation protocols and cell line.
Once standardized protocols for cardiomyocytes differentiation are developed, in what state should hPSC-CMs be assayed? From a pure physiologist's vantage point, it is attractive to study the singularized hPSC-CM. Isolated and electromechanically decoupled from neighboring cells, this state mimics traditional physiological experiments with isolated adult CMs. However, experiments with isolated CMs are often performed early after isolation, before the conditions of culture exert their confounding influences. Adult CMs de-differentiate when maintained in prolonged culture, exhibiting a higher diastolic potential, spontaneous activity, loss of T-tubular and sarcomeric organizational structure, and variable action potential phenotypes [73, 74] . Meanwhile, hPSC-CMs are kept in continual culture and are generally phenotyped following a recovery period after dissociation, and it is conceivable that dissociation to a single cell level may substantially alter cellular phenotype. Moreover, there is evidence that removal of the influence of nonmyocytes from hPSC-CMs in embryoid bodies by genetic selection results in a functional stalling of maturation [75] . Protocols for cellular dissociation vary, with some resembling traditional cell culture techniques [23••] , and others bearing resemblance to animal CM isolation [46] . Unlike freshly isolated adult CMs where the source is relatively homogeneous and the principle quality metric is Ca 2+ tolerance, heterogeneous starting populations of hPSC-CM may be differentially affected by dissociation protocols, intro-ducing survival biases. Finally, the appropriate cell plating density and optimal time window to assay hPSC-CMs following dissociation [76] requires exploration.
Streamlining phenotyping Conventional electrophysiology
How should hPSC-CMs be phenotyped in high-throughput screens? Since its inception by Neher and Sakmann [77] , conventional patch clamp electrophysiology has proven to be a rigorous method of evaluation and has previously been used to demonstrate the predictive power of hPSC-CM models for cardiotoxicity [20••] . Perhaps its biggest downside is that manual patch clamping is also tedious and slow. In contrast, commercial 96-well and 384-well automatic patch clamp devices based on glass pipets or planar electrodes are available, the latter having been utilized on commercial hPSC-CMs with an average success rate of 46 % and mean seal resistance of 1.4 GΩ with mean stability of~18 min [78, 79] . However, these automated systems have traditionally been employed for voltage-clamp recordings of individual currents in heterologous cell lines and may be less applicable for differentiated cells derived from hPSCs [80] . One possible advantage of patch clamp electrophysiology lies in the ability to directly augment the hPSC-CM physiology, such as by "electronically injecting" rectifier current I K1 using a dynamic clamp to model a more mature state [37] . The dynamic clamp may be an improvement over other studies that have employed negative current injection throughout the cardiac cycle to maintain diastolic potentials at more "adult" values between -80 and -100 mV [63, 35] . Finally, the successful throughput of all patch electrophysiology is critically dependent on membrane quality, which varies between cellular preparations. Particularly disadvantageous for drug studies, patch clamp electrophysiology tends to be limited in the capacity for prolonged or serial recordings.
Multi-electrode arrays
Another measure of the electrical activity which has grown in popularity is use of multi-electrode arrays (MEA) [81] [82] [83] 21] . MEAs consist of planar arrangements of electrodes that capture local extracellular field potentials from multicellular CM aggregates. As these systems permit simultaneous recordings from multiple electrodes, they are suited for high-throughput measurements, while their non-invasive nature facilitates serial or prolonged recordings. However, compared to traditional patch-clamp electrophysiology, MEAs do not yield as much direct information about the morphology of cellular action potentials, and recording is restricted to multicellular aggregates large enough to generate sufficient electrical signals.
Contractile motion/impedance analysis
Contractile motion and beat rate variability [84] can be measured noninvasively using impedance recordings, and systems for high-throughput have been commercially developed. Guo and colleagues [40] developed an assay utilizing confluent monolayers of hPSC-CMs. These authors assayed a panel of 83 drugs for concentrations that elicited arrhythmic beating and/or slowing of beat rate, noting that the resulting concentration correlated with clinical arrhythmia and QT-prolongation levels. Similar to MEA-based recording, impedance-based assays are non-invasive and amenable to highthroughput. However, while the contractile properties of cardiomyocytes correlate with their electrophysiology, the electromechanical coupling of hPSC-CMs is not as mature as their adult counterparts. Furthermore, the effects of some compounds that harbor independent or differential contractile vs. electrical toxicity may produce readouts that confound measurements of "true" arrhythmogenicity.
Fluorescent optical mapping
Fluorescent Optical "mapping" with voltage-sensitive and calcium-sensitive indicators is a well-established method of imaging electrical activity [85•] . AP morphology and wavefront propagation in whole hearts has been performed with the zwitterionic membrane dyes, di-4-ANEPPS and di-8-ANEPPS for years [85•] . These probes were recently combined with Ca 2+ imaging dyes and used to simultaneously image electrical and calcium dynamics in hPSC-CM monolayers [72••] . However, the ANEPPS dyes feature prominent phototoxicity and photobleaching that limit cumulative illumination and degrades signal quality [86] . Furthermore, these dyes have had limited application to the study of isolated cells [87] . While the newer redshifted probe di-4-ANBDQBS features a higher signal quality, its adequacy has yet to be evaluated for use with hPSC-CMs. In contrast, Ca
2+
-based dyes such as fluo-4 and rhod-2 have much lower toxicity and higher fluorescence [88] . Some hPSC-CM screens have used high-throughput imaging systems with fluo4-based Ca2+ transients as a surrogate reporter for electrical activity [89, 90] . In addition to small-molecule based membrane dyes, the field of genetically encoded voltage [91] [92] [93] [94] and calcium sensors [95] has been evolving rapidly. One of these voltage indicators, A242-ArcLight, was recently demonstrated to robustly report electrical activity in hPSC-CMs, with a signal to noise ratio of~22 dB when measured in single isolated cells with standard fluorescence microscopy [96] . As genetically encoded probes continue to offer improved signal-to-noise quality, photostability, and reduced toxicity, they may find a place in the non-invasive characterization of electrophysiology in hPSC-CM models.
Screening in practice
Once a suitable method of phenotypic evaluation is chosen, how would a high-throughput drug screen be conceived in practice? Numerous chemical libraries are commercially available for the purpose of drug screening, from small collections of characterized compounds to larger libraries of up to~1 million compounds with uncharacterized function. As hPSC-CM screening technology develops, initial efforts may be geared towards smaller libraries of characterized molecules where "hits" are more easily clinically translatable, such as from collections of US Food and Drug Administration (FDA) approved drugs. To minimize the confounding influence of cellular heterogeneity and experimental variation, multiple measurements could be taken for each condition or drug concentration. Data may also be recorded pre-drug and post-drug application, with each cell or cell aggregate being its own control. In the case of fluorescence evaluations and MEA recordings, cells may be arrayed multi-well configurations, with up to hundreds of cells or cell aggregates per well. For measures such as action potential duration having inherent rate dependence, rate control, such as by electric field stimulation, could be considered.
Furthermore, to ensure reproducibility, the relative purity of the cell type of interest should be considered. hPSC-CMs destined for screening purposes might be either freed of contaminating non-cardiomyocyte cell types prior to plating, or marked by fluorescent reporters that define and validate their identity as specific cell types. For example, reporters for the ventricular myosin light chain-2-isoform (MLC-2v), which has been demonstrated to be a marker for hPSCs committed to the ventricular lineage, could be utilized to obtain a ventricular lineage [63] . Similarly, as βMHC is the dominant isoform of the myosin heavy chain in the adult heart and detectable in EBs at around 90 days or later [65•] , it may be suitable as a marker of relative maturity. In addition to purity, future screens should optimize and report information on cell quality. It is foreseeable that the field may advance beyond small panels of expression markers and instead rely on multiple parameters, including incorporating functional ones towards an overall assessment of cell quality. Recently, Sheehy and colleagues [97] devised a 64-parameter quality assessment on commercially available murine pluripotent stem cell-derived cardiomyocytes based on structural (i.e., sarcomere alignment), electrophysiological (i.e., AP duration), and contractile performance, in comparison to freshly isolated neonatal ventricular myocytes.
Going forward
Current cardiotoxicity evaluations with animal cells and I Kr /hERG-expressing heterologous systems have limitations in their prediction of clinical toxicology. Compared to heterologous cell lines, hPSC-CM technology recapitulates at least some of the native milieu and intricacies of human cardiomyocytes, and thus holds promise to be a valuable tool drug discovery and disease modeling. Notably, the FDA and the Health and Environmental Sciences Institute (HESI) recently laid out a new paradigm for preclinical cardiotoxicity testing, which includes tests on stem-cell-derived cardiomyocytes [98] . However, efforts to date have been limited both by the variability, immaturity, and heterogeneity of cardiomyocytes produced by current protocols and by the labor-intensive nature of conventional phenotyping. In particular, the immature nature of the present iteration of hPSC-CM technology is a major barrier to clinical translatability. As techniques for the production of hPSC-CMs continue to advance and standardize, and we gain a clearer understanding of the reproducibility and predictive power of hPSC-CM assays, we can begin to use hPSC-CM screens in a widespread fashion. This will represent a significant advance, moving cardiovascular medicine closer to personalized therapies and targeted therapeutics. 
